SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

Author's Avatar
Aug 02, 2023

NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (“Biohaven” or the “Company”) (: BHVN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Biohaven and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On July 27, 2023, Biohaven issued a press release announcing, among other items, that “[o]n its SCA program, the FDA informed Biohaven that it would not review the recently submitted NDA application for troriluzole given that the study’s primary endpoint was not met and thus, would not permit a substantive review.”

On this news, Biohaven’s stock price fell $5.38 per share, or 22.61%, to close at $18.42 per share on July 27, 2023.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See

Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980